Keros Therapeutics, Inc (NASDAQ:KROS) Repositions Pipeline While Near-Term Valuation Remains Elevated
![]() |
Keros pursues clinical progress across multiple programs while balance-sheet strength contrasts with deep YoY revenue contraction; technicals suggest range-bound action with modest upside potential. A combination of bullish momentum signals and recent indicator reversals frames a cautious near-term view. |










